Raptor Pharmaceutical Corp.  

(Public, NASDAQ:RPTP)   Watch this stock  
Find more results for William D. Keltner
+0.16 (2.47%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.43 - 6.69
52 week 5.17 - 16.28
Open 6.54
Vol / Avg. 503,177.00/1.04M
Mkt cap 552.31M
P/E     -
Div/yield     -
EPS -0.93
Shares 85.10M
Beta 0.46
Inst. own 65%
Feb 24, 2016
Q4 2015 Raptor Pharmaceutical Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 10, 2015
Raptor Pharmaceutical Corp at Credit Suisse Healthcare Conference
Nov 5, 2015
Q3 2015 Raptor Pharmaceutical Corp Earnings Call - Webcast
Nov 5, 2015
Q3 2015 Raptor Pharmaceutical Corp Earnings Release
Sep 30, 2015
Raptor Pharmaceutical Corp at Leerink Partners Rare Disease Roundtable
Sep 9, 2015
Raptor Pharmaceutical Corp at FBR Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -56.57% -75.60%
Operating margin -43.37% -57.63%
EBITD margin - -56.14%
Return on average assets -22.82% -35.29%
Return on average equity -50.50% -135.56%
Employees 123 -
CDP Score - -


7 Hamilton Lndg Ste 100
NOVATO, CA 94949-8246
United States - Map
+1-415-4086200 (Phone)
+1-415-3828002 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company's product, PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine, received a marketing authorization from the European Commission (EC), as an orphan medicinal product for the management of nephropathic cystinosis in the European Union (EU). The Company's pipeline includes its delayed-release form of cysteamine, or RP103 and its oral 4-methylpyrazole, or Convivia. Its other product, Quinsair, is an inhaled formulation of levofloxacin used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Officers and directors

Llew Keltner Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Julie Anne Smith President, Chief Executive Officer Designate, Director
Age: 44
Bio & Compensation  - Reuters
Michael P. Smith Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Robert H. Uhl Managing Director
Bio & Compensation  - Reuters
David A Happel Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Krishna R. Polu M.D. Chief Medical Officer
Age: 41
Bio & Compensation  - Reuters
Georges Gemayel Ph.D. Director
Age: 54
Bio & Compensation  - Reuters
Gregg A. Lapointe CPA Director
Age: 56
Bio & Compensation  - Reuters
Christopher M. Starr Ph.D. Director
Age: 62
Bio & Compensation  - Reuters
Raymond William Anderson Independent Director
Age: 73
Bio & Compensation  - Reuters